|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EPX-100 is a first-generation antihistamine safely used to treat itch in the 1950-1960s. EPX-100 is not currently manufactured or available anywhere in the world. EPX-100 was found to be a powerful suppressor of spontaneous convulsive behavior and electrographic seizures in zebrafish disease models for DS. EPX-100 antiepileptic action is not through a histaminergic mechanism of action, but acts via modulation of serotonin (5HT) signaling pathways.
EPX-101, 102, and 103 are EPX-100 analogs, which have been fully confirmed with zebrafish DS disease models.
All of them were a potent suppressor of spontaneous convulsive behavior and electrographic seizures in zebrafish DS disease models.
EPX-200 is an FDA-approved weight gain management drug which acts via modulation of serotonin (5HT) signaling pathways. EPX-200 was found to be a powerful suppressor of spontaneous convulsive behavior and electrographic seizures in zebrafish disease models for DS. EPX-200 also showed promising clinical results in terms of reductions in seizure frequency and/or severity in a small group of DS patients.
EPX-300 is an FDA-approved antidepressant, anti-anxiety and sleep-inducing insomnia drug which acts via modulation of serotonin (5HT) signaling pathways. EPX-300 was found to be a powerful suppressor of spontaneous convulsive behavior and electrographic seizures in zebrafish disease models for DS.